Profile data is unavailable for this security.
About the company
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure. In addition, the Company is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic allergic contact dermatitis (ACD), a common occupational skin condition. It is conducting a Phase II trial of its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The Company is also developing product candidates for a number of chronic dermatological and inflammatory conditions.
- Revenue in USD (TTM)0.00
- Net income in USD-7.72m
- Incorporated2009
- Employees16.00
- LocationEdesa Biotech Inc100 Spy CrtMARKHAM L3R 5H6CanadaCAN
- Phone+1 (905) 475-1234
- Fax+1 (905) 475-1234
- Websitehttps://www.edesabiotech.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pieris Pharmaceuticals Inc | 42.81m | -24.54m | 13.70m | 46.00 | -- | 0.5121 | -- | 0.3201 | -22.94 | -22.94 | 38.03 | 21.64 | 0.6382 | -- | 13.42 | 930,652.20 | -36.58 | -28.41 | -57.30 | -39.69 | -- | -- | -57.33 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| Nexgel Inc | 4.09m | -3.16m | 13.83m | 19.00 | -- | 2.71 | -- | 3.38 | -0.5566 | -0.5566 | 0.7212 | 0.818 | 0.4027 | 3.81 | 9.57 | 215,263.20 | -31.39 | -44.61 | -38.80 | -56.19 | 15.16 | 5.02 | -77.95 | -180.98 | 1.46 | -- | 0.1396 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
| Microbot Medical Inc | 0.00 | -10.74m | 14.11m | 22.00 | -- | 2.55 | -- | -- | -1.08 | -1.08 | 0.00 | 0.3845 | 0.00 | -- | -- | 0.00 | -120.24 | -53.28 | -178.87 | -62.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.44 | -- | -31.76 | -- |
| Avalo Therapeutics Inc | 1.93m | -31.54m | 14.85m | 19.00 | -- | 1.58 | -- | 7.71 | -381.36 | -381.36 | 6.94 | 9.11 | 0.0708 | 128.50 | 1.87 | 101,315.80 | -116.06 | -99.64 | -228.35 | -154.42 | 33.25 | 84.69 | -1,638.65 | -613.58 | 1.82 | -5.67 | 0.00 | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
| Edesa Biotech Inc | 0.00 | -7.72m | 14.90m | 16.00 | -- | 2.51 | -- | -- | -2.60 | -2.60 | 0.00 | 1.85 | 0.00 | -- | -- | 0.00 | -79.13 | -- | -95.05 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
| Mannatech Inc | 131.96m | -2.24m | 15.10m | 213.00 | -- | 1.42 | -- | 0.1144 | -1.21 | -1.21 | 70.53 | 5.64 | 2.92 | 1.99 | 854.08 | 619,507.10 | -4.96 | 4.39 | -12.90 | 9.16 | 77.95 | 77.87 | -1.70 | 1.72 | 0.5093 | -5.81 | 0.1226 | 88.33 | -3.83 | -5.33 | 50.13 | -- | -20.38 | -- |
| Allied Corp | 21.51k | -9.00m | 15.34m | -- | -- | -- | -- | 713.32 | -0.0915 | -0.0915 | 0.0002 | -0.0711 | 0.0051 | 1.65 | 0.1441 | -- | -214.39 | -- | -- | -- | -6,919.57 | -- | -41,861.41 | -- | 0.0333 | -31.86 | -- | -- | -56.46 | -- | 31.30 | -- | -- | -- |
| Tonix Pharmaceuticals Holding Corp | 7.77m | -116.66m | 15.50m | 103.00 | -- | 0.1019 | -- | 2.00 | -8.62 | -8.62 | 0.4572 | 1.80 | 0.0409 | -- | -- | 75,417.48 | -61.38 | -59.46 | -68.01 | -65.92 | 38.97 | -- | -1,501.78 | -5,126.73 | 1.81 | -- | 0.0779 | -- | -- | -- | 0.1874 | -- | 320.57 | -- |
| Psyence Biomedical Ltd | 0.00 | 1.52m | 15.53m | -- | -- | -- | 10.25 | -- | -0.0442 | -0.0442 | 0.00 | -0.3979 | 0.00 | -- | -- | -- | 1.13 | -- | 1.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.63 | -- | -- | -- |
| Oncotelic Therapeutics Inc | 70.00k | -7.90m | 15.71m | 22.00 | -- | 1.30 | -- | 224.39 | -0.02 | -0.02 | 0.0002 | 0.0304 | 0.0021 | -- | 3.61 | 3,181.82 | -24.82 | -25.03 | -49.08 | -48.76 | -- | -- | -11,722.94 | -1,692.93 | -- | -0.4788 | 0.5199 | -- | -- | -- | -255.12 | -- | -- | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 15.82m | 4.00 | -- | -- | -- | 21,098.93 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| Traws Pharma Inc | 226.00k | -18.95m | 16.09m | 16.00 | -- | 1.25 | -- | 71.20 | -0.9029 | -0.9029 | 0.0108 | 0.5081 | 0.0073 | -- | 9.62 | 14,125.00 | -61.07 | -63.43 | -84.61 | -85.72 | -- | -- | -8,384.07 | -3,257.92 | -- | -- | 0.00 | -- | 0.00 | -28.72 | 0.0844 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| CM Management LLCas of 31 Dec 2023 | 62.00k | 1.96% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 15.70k | 0.50% |
| Geode Capital Management LLCas of 31 Dec 2023 | 14.68k | 0.46% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 11.33k | 0.36% |
| UBS Securities LLCas of 31 Dec 2023 | 4.28k | 0.14% |
| Tower Research Capital LLCas of 31 Dec 2023 | 1.56k | 0.05% |
| Vanguard Global Advisers LLCas of 31 Dec 2023 | 643.00 | 0.02% |
| RBC Dominion Securities, Inc. (Investment Management)as of 31 Dec 2023 | 217.00 | 0.01% |
| TD Waterhouse Canada, Inc.as of 31 Dec 2023 | 142.00 | 0.00% |
| Fifth Third Bank, NA (Investment Management)as of 31 Mar 2024 | 100.00 | 0.00% |
